Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3035912rdf:typepubmed:Citationlld:pubmed
pubmed-article:3035912lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:3035912lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:3035912lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:3035912lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:3035912lifeskim:mentionsumls-concept:C0020402lld:lifeskim
pubmed-article:3035912lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:3035912lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:3035912pubmed:issue3lld:pubmed
pubmed-article:3035912pubmed:dateCreated1987-7-8lld:pubmed
pubmed-article:3035912pubmed:abstractTextSixteen patients with advanced non-small-cell lung cancer were treated with the combination of cis-platinum, 5-fluorouracil, and hydroxyurea. There were two complete responses (lasting 16 weeks each) and one partial response (lasting 12 weeks). Toxicity was manageable, but responders were unable to tolerate further therapy. Despite the obtaining of complete responses, the overall benefit of this particular combination requires further clinical investigation.lld:pubmed
pubmed-article:3035912pubmed:languageenglld:pubmed
pubmed-article:3035912pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3035912pubmed:citationSubsetIMlld:pubmed
pubmed-article:3035912pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3035912pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3035912pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3035912pubmed:statusMEDLINElld:pubmed
pubmed-article:3035912pubmed:monthJunlld:pubmed
pubmed-article:3035912pubmed:issn0277-3732lld:pubmed
pubmed-article:3035912pubmed:authorpubmed-author:DimitrovN VNVlld:pubmed
pubmed-article:3035912pubmed:authorpubmed-author:AxelsonJ AJAlld:pubmed
pubmed-article:3035912pubmed:authorpubmed-author:ClarkR HRHlld:pubmed
pubmed-article:3035912pubmed:issnTypePrintlld:pubmed
pubmed-article:3035912pubmed:volume10lld:pubmed
pubmed-article:3035912pubmed:ownerNLMlld:pubmed
pubmed-article:3035912pubmed:authorsCompleteYlld:pubmed
pubmed-article:3035912pubmed:pagination243-4lld:pubmed
pubmed-article:3035912pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:meshHeadingpubmed-meshheading:3035912-...lld:pubmed
pubmed-article:3035912pubmed:year1987lld:pubmed
pubmed-article:3035912pubmed:articleTitlecis-platinum, 5-fluorouracil, and hydroxyurea in the treatment of advanced non-small-cell lung cancer. A phase II study.lld:pubmed
pubmed-article:3035912pubmed:publicationTypeJournal Articlelld:pubmed